A5052556995- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Viral-associated cancers and disorders
- Histone Deacetylase Inhibitors Research
- T-cell and Retrovirus Studies
- Protein Degradation and Inhibitors
- Phosphodiesterase function and regulation
- Cancer, Lipids, and Metabolism
- Peptidase Inhibition and Analysis
- Hepatitis C virus research
- Polyomavirus and related diseases
- Ferroptosis and cancer prognosis
- Ion channel regulation and function
- Hepatitis B Virus Studies
- Ubiquitin and proteasome pathways
- Cardiac electrophysiology and arrhythmias
- Cancer-related molecular mechanisms research
- Chronic Lymphocytic Leukemia Research
National Cancer Centre Singapore
2021-2024
Abstract Background Natural killer/T-cell lymphoma (NKTL) is a rare type of aggressive and heterogeneous non-Hodgkin's (NHL) with poor prognosis limited therapeutic options. Therefore, there an urgent need to exploit potential novel targets for the treatment NKTL. Histone deacetylase (HDAC) inhibitor chidamide was recently approved treating relapsed/refractory peripheral T-cell (PTCL) patients. However, its efficacy in NKTL remains unclear. Methods We performed phase II clinical trial...
Loss of ferroptosis contributes to the development human cancer, and restoration has been demonstrated as a potential therapeutic strategy in cancer treatment. However, mechanisms how escape ovarian (OV) are not well elucidated. Here, we show that negative regulation signatures correlated with tumorigenesis OV were associated poor prognosis, suggesting represents OV. High-throughput drug screening kinase inhibitor library identified MEK inhibitors inducers cells. We further...
Diffuse large B-cell lymphoma (DLBCL) exhibits frequent inactivating mutations of the histone acetyltransferase CREBBP, highlighting attractiveness targeting CREBBP deficiency as a therapeutic strategy. In this study, we demonstrate that chidamide, novel deacetylase (HDAC) inhibitor, is effective in treating subgroup relapsed/refractory DLBCL patients, achieving an overall response rate (ORR) 25.0% and complete (CR) 15.0%. However, clinical to chidamide remains poor, most patients exhibit...
XPO1 is an attractive and promising therapeutic target frequently overexpressed in multiple hematological malignancies. The clinical use of inhibitors natural killer/T-cell lymphoma (NKTL) not well documented. Here, we demonstrated that overexpression indicator poor prognosis patients with NKTL. compassionate the inhibitor selinexor combination chemotherapy showed favorable outcomes three refractory/relapsed (R/R) NKTL patients. Selinexor induced complete tumor regression prolonged survival...
Abstract Introduction: Brincidofovir (BCV) is a biologically-active acyclic nucleoside phosphonate and clinically-approved anti-viral agent. Recently, BCV has been demonstrated to display potent anti-proliferative immunogenic properties in NK/T cell lymphoma (NKTCL). However, its effect on other types remain unclear. Methods: We investigated an expanded cohort of B-cell cell-lines (diffuse large [DLBCL], n = 16; Burkitt lymphoma, 2; Hodgkin 1), comparison with NKTCL lines (n 11). Mouse...
SKA-346 is a K Ca 3.1-selective activator.
Introduction: Natural killer/T-cell lymphoma (NKTCL) is an aggressive Epstein-Barr virus (EBV)-associated malignancy which prevalent in Asian countries. Brincidofovir (BCV), a lipid conjugated form of cidofovir, biologically-active acyclic nucleoside phosphonate recently shown to exhibit both antiviral and antitumor properties. Methods: We investigated BCV NKTCL cell-lines (n = 11) mouse xenograft models. Whole exome sequencing, bulk RNAseq single cell (scRNAseq) were employed examine...